Cerevel Therapeutics CERE Stock
Cerevel Therapeutics Price Chart
Cerevel Therapeutics CERE Financial and Trading Overview
Cerevel Therapeutics stock price | 44.96 USD |
Previous Close | 34.17 USD |
Open | 33.97 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1400 |
Day's Range | 33.93 - 35.59 USD |
52 Week Range | 22.63 - 41.46 USD |
Volume | 958.61K USD |
Avg. Volume | 567.97K USD |
Market Cap | 5.55B USD |
Beta (5Y Monthly) | 1.47912 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 36.33 USD |
CERE Valuation Measures
Enterprise Value | 5.16B USD |
Trailing P/E | N/A |
Forward P/E | -12.5461 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 12.846769 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -13.24 |
Trading Information
Cerevel Therapeutics Stock Price History
Beta (5Y Monthly) | 1.47912 |
52-Week Change | 47.90% |
S&P500 52-Week Change | 20.43% |
52 Week High | 41.46 USD |
52 Week Low | 22.63 USD |
50-Day Moving Average | 30.51 USD |
200-Day Moving Average | 29.18 USD |
CERE Share Statistics
Avg. Volume (3 month) | 567.97K USD |
Avg. Daily Volume (10-Days) | 545.72K USD |
Shares Outstanding | 156.83M |
Float | 59.07M |
Short Ratio | 9.01 |
% Held by Insiders | 17.55% |
% Held by Institutions | 88.81% |
Shares Short | 5.02M |
Short % of Float | 11.38% |
Short % of Shares Outstanding | 3.20% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -31.86% |
Return on Equity (ttm) | -81.30% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -389763008 USD |
Net Income Avi to Common (ttm) | -387503008 USD |
Diluted EPS (ttm) | -2.73 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 826.99M USD |
Total Cash Per Share (mrq) | 5.27 USD |
Total Debt (mrq) | 438.71M USD |
Total Debt/Equity (mrq) | 101.62 USD |
Current Ratio (mrq) | 13.355 |
Book Value Per Share (mrq) | 2.754 |
Cash Flow Statement
Operating Cash Flow (ttm) | -320462016 USD |
Levered Free Cash Flow (ttm) | -179429872 USD |
Profile of Cerevel Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | 222 Jacobs Street |
ZIP | 02141 |
Phone | 844 304 2048 |
Website | https://www.cerevel.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 319 |
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Q&A For Cerevel Therapeutics Stock
What is a current CERE stock price?
Cerevel Therapeutics CERE stock price today per share is 44.96 USD.
How to purchase Cerevel Therapeutics stock?
You can buy CERE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cerevel Therapeutics?
The stock symbol or ticker of Cerevel Therapeutics is CERE.
Which industry does the Cerevel Therapeutics company belong to?
The Cerevel Therapeutics industry is Biotechnology.
How many shares does Cerevel Therapeutics have in circulation?
The max supply of Cerevel Therapeutics shares is 182.2M.
What is Cerevel Therapeutics Price to Earnings Ratio (PE Ratio)?
Cerevel Therapeutics PE Ratio is 0.00000000 now.
What was Cerevel Therapeutics earnings per share over the trailing 12 months (TTM)?
Cerevel Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Cerevel Therapeutics company belong to?
The Cerevel Therapeutics sector is Healthcare.
Cerevel Therapeutics CERE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}